DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo The first patient has been dosed in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results